A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

NCT06993792 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing the investigational drug orforglipron (LY3502970) in adults who have obesity or are overweight, with or without type 2 diabetes, to observe how the drug is distributed among participants.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind screening study

Participants 1,200 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2025-05 · est. completion 2027-08

Where 80 sites · Argentina, China, Czechia, Germany, Japan, Puerto Rico, United States

What this study is testing ClinicalTrials.gov NCT06993792 ↗

Description as written by the study sponsor.

The purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants who have obesity or overweight with or without type 2 diabetes. Participants will be screened for about 4 weeks, after which they will enroll into either J2A-MC-GZP1, NCT06972459 (do not have type 2 diabetes) or J2A-MC-GZP2, NCT06972472 (have type 2 diabetes).

Treatments tested

Orforglipron Drug

Administered orally
Placebo Drug

Administered orally

Main thing measured	Number of Participants Allocated to Each Study
Sponsor	Eli Lilly and Company
Conditions studied	Obesity, Overweight, Type 2 Diabetes
GLP-1 drugs	orforglipron

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06993792 ↗